Proxy Votes Now

Home › Funds › John Hancock › Small Cap Stock Trust

Small Cap Stock Trust (JAGPX) proxy voting record 2025-2026

Fund family: John Hancock · Filed by JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 756913) · SEC series S000008343

Share classes and tickers: JAGPX (C000022831), JAGQX (C000022833), JESGX (C000022832)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 757 with, 4 against, 14 abstentions (not counted as with management); 6 items carried no recommendation. Shareholder proposals: 4 FOR, 0 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with John Hancock as a whole

The same two figures as John Hancock’s manager page (290,519 ballot items across 99 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsJohn HancockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)95.0%73690.1%242,172
Backed environmental and social shareholder proposals at US companiesn/a013.4%1,935

Where this fund voted differently from most John Hancock funds

Each ballot item this fund voted is set against the votes of the other John Hancock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most John Hancock funds on 115 items (16.3% of the 704 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
VIPER ENERGY, INC.2026-05-19The approval, on an advisory basis, of the compensation of the Company's named executive officers.ForAGAINST — 9 of 9 John Hancock fundsForApproved, 86.8% support
SANMINA CORPORATION2026-03-09Shareholder To consider and vote upon the stockholder proposal entitled ''Independent Board Chairman,'' requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO.ForAGAINST — 8 of 8 John Hancock fundsAgainst—
SANMINA CORPORATION2026-03-09To elect eight directors of Sanmina Corporation: Krish PrabhuAgainstFOR — 8 of 8 John Hancock fundsAgainstPassed (calculated), 93.9% support
AXSOME THERAPEUTICS, INC.2026-06-05DIRECTOR: Mark SaadForABSTAIN — 8 of 8 John Hancock fundsFor—
AXSOME THERAPEUTICS, INC.2026-06-05DIRECTOR: Susan Mahony, PhD., MBAForABSTAIN — 8 of 8 John Hancock fundsFor—
WINGSTOP INC.2026-05-21Approve, on an advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 8 of 8 John Hancock fundsForApproved, 50.4% support
COMFORT SYSTEMS USA, INC.2026-05-18DIRECTOR: William J. SandbrookAbstainFOR — 7 of 7 John Hancock fundsAgainst—
CASELLA WASTE SYSTEMS, INC.2026-06-04To elect the following nominees as Class II directors of the Company to serve until the 2029 Annual Meeting of Stockholders: Emily Nagle GreenForWITHHOLD — 7 of 7 John Hancock fundsForElected, 66.5% support
CASELLA WASTE SYSTEMS, INC.2026-06-04To elect the following nominees as Class II directors of the Company to serve until the 2029 Annual Meeting of Stockholders: Michael L. BattlesForWITHHOLD — 7 of 7 John Hancock fundsForElected, 73.4% support
CARGURUS, INC.2026-06-03DIRECTOR: Langley SteinertForABSTAIN — 7 of 7 John Hancock fundsFor—
CARGURUS, INC.2026-06-03DIRECTOR: Manik GuptaForABSTAIN — 7 of 7 John Hancock fundsFor—
CLEAR SECURE, INC.2026-06-10Approval of, on an advisory basis, the compensation of our named executive officers.ForAGAINST — 6 of 6 John Hancock fundsForApproved, 95.4% support
HIMS & HERS HEALTH, INC.2026-06-11Advisory approval of the Company's executive compensation.AgainstFOR — 6 of 6 John Hancock fundsAgainstPassed (calculated), 99.3% support
SCHOLAR ROCK HOLDING CORPORATION2026-06-04To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 6 of 6 John Hancock fundsForApproved, 61.7% support
UNIVERSAL DISPLAY CORPORATION2026-06-18Advisory resolution to approve the compensation of the Company's named executive officers.ForAGAINST — 6 of 6 John Hancock fundsForPassed (calculated), 80.4% support
CORE SCIENTIFIC, INC.2026-05-12To approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAGAINST — 6 of 6 John Hancock fundsForApproved, 63.7% support
ALIGNMENT HEALTHCARE INC2026-06-04Election of Directors David HodgsonForWITHHOLD — 6 of 6 John Hancock fundsFor—
ALIGNMENT HEALTHCARE INC2026-06-04Election of Directors Jacqueline KosecoffForWITHHOLD — 6 of 6 John Hancock fundsFor—
ALIGNMENT HEALTHCARE INC2026-06-04Election of Directors Jody BilneyForWITHHOLD — 6 of 6 John Hancock fundsFor—
JAMES HARDIE INDUSTRIES PLC2025-10-29Increase Non-Executive Director Fee PoolForAGAINST — 5 of 5 John Hancock funds——
IONQ, INC.2026-06-16To elect two Class II directors to hold office until our 2029 Annual Meeting of Stockholders and until a successor is duly elected and qualified or until earlier resignation or removal. Kathryn K. ChouForWITHHOLD — 5 of 5 John Hancock fundsFor—
PROTAGONIST THERAPEUTICS, INC.2026-06-17DIRECTOR: L.T. Williams, MD, PhDForABSTAIN — 5 of 5 John Hancock fundsFor—
DIGITALOCEAN HOLDINGS, INC.2026-06-15Election of Class II Directors Pueo KefferForWITHHOLD — 5 of 5 John Hancock fundsFor—
DIGITALOCEAN HOLDINGS, INC.2026-06-15Election of Class II Directors Warren AdelmanForWITHHOLD — 5 of 5 John Hancock fundsFor—
PJT PARTNERS INC.2026-06-18To elect the three nominees for Class II directors listed below, each to serve for a three-year term expiring at the 2029 annual meeting of shareholders (Proposal 1): Thomas M. RyanForWITHHOLD — 5 of 5 John Hancock fundsForPassed (calculated), 84.6% support
Show all 115
Items 26 to 115.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
VERRA MOBILITY CORPORATION2026-05-19DIRECTOR: Patrick J. ByrneAbstainFOR — 5 of 5 John Hancock fundsAgainst—
SITIME CORPORATION2026-05-29To approve, on an advisory basis, the compensation of SiTime's named executive officers as disclosed in SiTime's proxy statement.ForAGAINST — 8 of 9 John Hancock fundsForApproved, 82.1% support
MKS, INC.2026-05-11The approval, on an advisory basis, of a Company proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 25%.AbstainFOR — 10 of 12 John Hancock fundsAgainstPassed (calculated), 98.5% support
GLAUKOS CORPORATION2026-05-28DIRECTOR: Denice M. TorresForABSTAIN — 4 of 4 John Hancock fundsFor—
PACS GROUP, INC.2026-06-10DIRECTOR: Evelyn DilsaverForABSTAIN — 4 of 4 John Hancock fundsFor—
EXLSERVICE HOLDINGS, INC.2026-06-16Election of Directors Kristy PipesAgainstFOR — 4 of 4 John Hancock fundsAgainst—
HIMS & HERS HEALTH, INC.2026-06-11DIRECTOR: Andrew DudumForABSTAIN — 4 of 4 John Hancock fundsFor—
HIMS & HERS HEALTH, INC.2026-06-11DIRECTOR: Christopher PayneForABSTAIN — 4 of 4 John Hancock fundsFor—
CORE SCIENTIFIC, INC.2026-05-12Election of Directors Eric WeissForWITHHOLD — 4 of 4 John Hancock fundsFor—
CORE SCIENTIFIC, INC.2026-05-12Election of Directors Jeff BoothForWITHHOLD — 4 of 4 John Hancock fundsFor—
XENON PHARMACEUTICALS INC2026-06-02To approve the Corporation's 2026 Equity Incentive Plan;ForAGAINST — 4 of 4 John Hancock fundsForApproved, 68.0% support
THE VITA COCO COMPANY, INC.2026-06-03DIRECTOR: Kenneth SadowskyForABSTAIN — 4 of 4 John Hancock fundsFor—
VIRIDIAN THERAPEUTICS, INC.2026-06-02To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. Tomas KiselakWithholdFOR — 4 of 4 John Hancock fundsAgainst—
CELCUITY INC.2026-05-14DIRECTOR: David F. DalveyForABSTAIN — 4 of 4 John Hancock fundsFor—
CELCUITY INC.2026-05-14DIRECTOR: Polly A. MurphyForABSTAIN — 4 of 4 John Hancock fundsFor—
CELCUITY INC.2026-05-14DIRECTOR: Richard E. BullerForABSTAIN — 4 of 4 John Hancock fundsFor—
CELCUITY INC.2026-05-14To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan.AgainstFOR — 4 of 4 John Hancock fundsAgainst—
CALIX, INC.2026-05-14To approve 672,300 shares of common stock reserved for issuance for the matching component of the Calix, Inc. Stock Purchase and Matching Plan.ForAGAINST — 4 of 4 John Hancock fundsForPassed (calculated), 81.5% support
GENEDX HOLDINGS CORP.2026-06-18DIRECTOR: Katherine StuelandForABSTAIN — 4 of 4 John Hancock fundsFor—
GENIUS SPORTS LIMITED2025-12-10an ordinary resolution seeking approval of the re-appointment of Daniel Burns as a Class I Director of the Company for a term of three years to expire at the third annual general meeting of the Company's shareholders following such election and until he ceases to serve in his office in accordance wiForAGAINST — 4 of 4 John Hancock fundsFor—
AMERESCO, INC. (AMRC)2026-06-04Elect two (2) directors to the Ameresco, Inc. Board of Directors for a three-year term or until their successors are elected and qualified. Claire Hughes-JohnsonForWITHHOLD — 4 of 4 John Hancock fundsFor—
AMERESCO, INC. (AMRC)2026-06-04Elect two (2) directors to the Ameresco, Inc. Board of Directors for a three-year term or until their successors are elected and qualified. Frank V. WisneskiForWITHHOLD — 4 of 4 John Hancock fundsFor—
AMERESCO, INC. (AMRC)2026-06-04To approve an amendment to Ameresco's 2020 Stock Incentive Plan (''Plan'') to increase the number of shares of Ameresco, Inc. Class A Common Stock authorised for issuance under the Plan by 3,200,000 from 5,000,000 to 8,200,000 as described in the Ameresco, Inc. Proxy Statement.ForAGAINST — 4 of 4 John Hancock fundsFor—
BLOOM ENERGY CORPORATION2026-05-21DIRECTOR: Barbara BurgerForABSTAIN — 6 of 7 John Hancock fundsFor—
BLOOM ENERGY CORPORATION2026-05-21DIRECTOR: Eddy ZervigonForABSTAIN — 6 of 7 John Hancock fundsFor—
NEXTRACKER INC.2025-08-18DIRECTOR: Jeffrey GuldnerForABSTAIN — 6 of 7 John Hancock fundsFor—
BRIDGEBIO PHARMA, INC.2026-06-22DIRECTOR: Hannah A. Valantine, MDForABSTAIN — 6 of 7 John Hancock fundsFor—
BRIDGEBIO PHARMA, INC.2026-06-22To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares.ForAGAINST — 6 of 7 John Hancock fundsForApproved, 82.9% support
LIFE TIME GROUP HOLDINGS, INC.2026-04-22DIRECTOR: J. Kristofer GalashanForABSTAIN — 8 of 10 John Hancock fundsFor—
LIFE TIME GROUP HOLDINGS, INC.2026-04-22DIRECTOR: Jennifer PomerantzForABSTAIN — 8 of 10 John Hancock fundsFor—
LIFE TIME GROUP HOLDINGS, INC.2026-04-22DIRECTOR: Jonathan CosletForABSTAIN — 8 of 10 John Hancock fundsFor—
CARGURUS, INC.2026-06-03To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for 2025.AgainstFOR — 6 of 7 John Hancock fundsAgainst—
HAMILTON LANE INCORPORATED2025-09-04Advisory, non-binding vote to approve named executive officer compensation.ForAGAINST — 7 of 9 John Hancock fundsForApproved, 76.2% support
GLAUKOS CORPORATION2026-05-28Approval, on an advisory basis, of the compensation of the Company's named executive officers.AgainstFOR — 5 of 6 John Hancock fundsAgainstPassed (calculated), 91.8% support
PACS GROUP, INC.2025-12-19To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.AgainstFOR — 3 of 3 John Hancock fundsAgainst—
LOAR HOLDINGS2026-06-02DIRECTOR: Alison BombergForABSTAIN — 3 of 3 John Hancock fundsFor—
XOMETRY, INC.2026-06-16To elect three Class II directors, each to hold office until the Company's Annual Meeting of Stockholders in 2029. Fabio RosatiForWITHHOLD — 3 of 3 John Hancock fundsFor—
XOMETRY, INC.2026-06-16To elect three Class II directors, each to hold office until the Company's Annual Meeting of Stockholders in 2029. Katharine WeymouthForWITHHOLD — 3 of 3 John Hancock fundsFor—
RUSH ENTERPRISES, INC.2026-05-19DIRECTOR: Dr. Kennon H. GuglielmoForABSTAIN — 5 of 6 John Hancock fundsFor—
RUSH ENTERPRISES, INC.2026-05-19DIRECTOR: Raymond J. ChessForABSTAIN — 5 of 6 John Hancock fundsFor—
RUSH ENTERPRISES, INC.2026-05-19DIRECTOR: Troy A. ClarkeForABSTAIN — 5 of 6 John Hancock fundsFor—
ADAPTIVE BIOTECHNOLOGIES CORPORATION2026-06-05To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2029 annual meeting of shareholders. Robert Hershberg, PhD, MDForWITHHOLD — 3 of 3 John Hancock fundsFor—
ENPHASE ENERGY, INC.2026-05-13To approve an amendment and restatement of our 2021 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,000,000 shares.ForAGAINST — 3 of 3 John Hancock fundsForApproved, 78.7% support
AVEPOINT, INC.2026-05-05DIRECTOR: Jeff EpsteinForABSTAIN — 3 of 3 John Hancock fundsFor—
AGILYSYS, INC.2025-09-04Election of Directors: Donald A. ColvinAgainstFOR — 3 of 3 John Hancock fundsAgainstElected, 97.1% support
AMPLITUDE, INC.2026-06-09DIRECTOR: Catherine WongForABSTAIN — 3 of 3 John Hancock fundsFor—
AMPLITUDE, INC.2026-06-09DIRECTOR: Curtis LiuForABSTAIN — 3 of 3 John Hancock fundsFor—
AMPLITUDE, INC.2026-06-09DIRECTOR: Pat GradyForABSTAIN — 3 of 3 John Hancock fundsFor—
MINERALYS THERAPEUTICS, INC.2026-05-212 wordings Election of Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders: Srinivas Akkaraju, M.D., Ph.D.ForWITHHOLD — 3 of 3 John Hancock fundsForPassed (calculated), 60.6% support
VOYAGER TECHNOLOGIES, INC.2026-05-29DIRECTOR: Marian JohForABSTAIN — 3 of 3 John Hancock fundsFor—
ZURN ELKAY WATER SOLUTIONS CORPORATION2026-04-30Advisory vote to approve the compensation of Zurn Elkay's named executive officers, as disclosed in "Compensation Discussion and Analysis" and "Executive Compensation" in the Proxy Statement.AgainstFOR — 6 of 8 John Hancock fundsAgainstPassed (calculated), 87.6% support
JAMES HARDIE INDUSTRIES PLC2025-10-29Grant of Return on Capital Employed Restricted Stock Units to CEOForAGAINST — 4 of 5 John Hancock fundsFor—
JAMES HARDIE INDUSTRIES PLC2025-10-29To receive and consider the remuneration report for fiscal year 2025ForAGAINST — 4 of 5 John Hancock fundsFor—
PROTAGONIST THERAPEUTICS, INC.2026-06-17DIRECTOR: Dinesh V. Patel, Ph.D.ForABSTAIN — 4 of 5 John Hancock fundsFor—
PROTAGONIST THERAPEUTICS, INC.2026-06-17To approve the adoption of the Company's 2026 Equity Incentive Plan.ForAGAINST — 4 of 5 John Hancock fundsForApproved, 84.4% support
INTAPP, INC2025-11-18DIRECTOR: Beverly AllenForABSTAIN — 4 of 5 John Hancock fundsFor—
INTAPP, INC2025-11-18DIRECTOR: Marie WieckForABSTAIN — 4 of 5 John Hancock fundsFor—
CRINETICS PHARMACEUTICALS, INC.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Caren DeardorfForWITHHOLD — 4 of 5 John Hancock fundsFor—
CRINETICS PHARMACEUTICALS, INC.2026-06-18To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders; Stephanie S. Okey, M.S.ForWITHHOLD — 4 of 5 John Hancock fundsFor—
NUVALENT, INC.2026-06-16Election of the following nominees as Class II directors: Michael L. Meyers, M.D., Ph.D.ForWITHHOLD — 4 of 5 John Hancock fundsForElected, 81.5% support
HAMILTON LANE INCORPORATED2025-09-04DIRECTOR: Hartley R. RogersForABSTAIN — 5 of 7 John Hancock fundsFor—
STRIDE, INC.2025-12-04Approval, on a non-binding advisory basis, of the compensation of the named executive officers of the Company;AgainstFOR — 5 of 7 John Hancock fundsAgainstApproved, 81.9% support
AMERICAN HEALTHCARE REIT, INC.2026-06-24For the election of Jeffrey T. Hanson, Danny Prosky, Mathieu B. Streiff, Scott A. Estes, Brian J. Flornes, Dianne Hurley, Marvin R. O'Quinn, Valerie Richardson and Wilbur H. Smith III to serve as Directors until the Annual Meeting of Stockholders of American Healthcare REIT, Inc. to be held in the yForWITHHOLD — 6 of 9 John Hancock fundsFor—
STANDARDAERO, INC.2026-06-25DIRECTOR: Douglas V. BrandelyForABSTAIN — 6 of 10 John Hancock fundsFor—
STANDARDAERO, INC.2026-06-25DIRECTOR: Stefan WeingartnerForABSTAIN — 6 of 10 John Hancock fundsFor—
STANDARDAERO, INC.2026-06-25DIRECTOR: Wendy M. MasielloForABSTAIN — 6 of 10 John Hancock fundsFor—
REVOLUTION MEDICINES, INC.2026-06-18DIRECTOR: Alexis BorisyForABSTAIN — 3 of 4 John Hancock fundsFor—
SPYRE THERAPEUTICS INC.2026-05-27DIRECTOR: Laurie StelzerForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: David HallalForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Katie PengForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Kristina BurowForABSTAIN — 3 of 4 John Hancock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Michael GilmanForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Arlene M. MorrisForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Dr. Chris CainForABSTAIN — 3 of 4 John Hancock fundsFor—
COGENT BIOSCIENCES, INC.2026-06-09DIRECTOR: Todd ShegogForABSTAIN — 3 of 4 John Hancock fundsFor—
DIANTHUS THERAPEUTICS, INC.2026-05-21To elect Class II directors, to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorgeForWITHHOLD — 3 of 4 John Hancock fundsFor—
DISC MEDICINE, INC.2026-06-18To elect each of the following Class III nominees to the Board of Directors as set forth below: Donald Nicholson, Ph.D.ForWITHHOLD — 3 of 4 John Hancock fundsFor—
MBX BIOSCIENCES2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. MathersForWITHHOLD — 3 of 4 John Hancock fundsFor—
MBX BIOSCIENCES2026-06-04Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholder and until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Patrick J. HeronForWITHHOLD — 3 of 4 John Hancock fundsFor—
INNOVEX INTERNATIONAL, INC.2026-05-07To elect the nominees named in the Proxy Statement as directors to serve for a three-year term. John LovoiAgainstFOR — 3 of 4 John Hancock fundsAgainst—
VAXCYTE, INC.2026-06-15DIRECTOR: Halley Gilbert, J.D.ForABSTAIN — 5 of 9 John Hancock fundsFor—
VAXCYTE, INC.2026-06-15DIRECTOR: Olivier Brandicourt MDForABSTAIN — 5 of 9 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Bruce Booth, D.Phil.ForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Elena Ridloff, CFAForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: John Maraganore, Ph.D.ForABSTAIN — 4 of 7 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Nello Mainolfi, Ph.D.ForABSTAIN — 4 of 7 John Hancock fundsFor—
RUBRIK, INC.2026-06-03DIRECTOR: Asheem ChandnaForABSTAIN — 2 of 3 John Hancock fundsFor—
LOAR HOLDINGS2026-06-02DIRECTOR: Margaret McGetrickForABSTAIN — 2 of 3 John Hancock fundsFor—
LOAR HOLDINGS2026-06-02DIRECTOR: Raja BobbiliForABSTAIN — 2 of 3 John Hancock fundsFor—
ENPHASE ENERGY, INC.2026-05-13DIRECTOR: Benjamin KortlangAbstainFOR — 2 of 3 John Hancock fundsAgainst—

Download all 115 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 90.7% of this fund’s 775 such votes could be given a sector; the other 72 (9.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care23000.0%
Consumer Discretionary15421.3%
Technology11810.8%
Industrials6811.5%
Finance6000.0%
Real Estate3500.0%
Energy1900.0%
Utilities1000.0%
Consumer Staples900.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4820
Say-on-Pay1180
Audit-related1100
Corporate Governance352
Compensation250
Capital Structure160
Other50
Shareholder Rights and Defenses52
Extraordinary Transactions10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
XOMETRY, INC.June 16, 2026$10M50
AMERICAN HEALTHCARE REIT, INC.June 24, 2026$6M110
HINGE HEALTH, INC.June 3, 2026$6M30
THE VITA COCO COMPANY, INC.June 3, 2026$6M50
ZURN ELKAY WATER SOLUTIONS CORPORATIONApril 30, 2026$6M50
NEXTRACKER INC.August 18, 2025$6M50
LIFE TIME GROUP HOLDINGS, INC.April 22, 2026$5M70
MKS, INC.May 11, 2026$5M81

Notable votes against management

MeetingCompanyProposalFundMgmt
May 11, 2026MKS, INC.A shareholder proposal to reduce the threshold percentage of shareholders required to call a special meeting of shareholders from 40% to 10%, if properly presented at the meeting. Shareholder proposalForAgainst
June 16, 2026FIVE BELOW, INC.Shareholder proposal requesting that provisions in the Company's governance documents requiring greater than a simple majority shareholder vote be changed to a simple majority vote standard. Shareholder proposalForAgainst
March 9, 2026SANMINA CORPORATIONTo consider and vote upon the stockholder proposal entitled ''Independent Board Chairman,'' requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO. Shareholder proposalForAgainst
May 14, 2026CALIX, INC.To hold an advisory vote on a stockholder proposal relating to a simple majority vote. Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

797 ballot items at 113 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Small Cap Stock Trust (JAGPX) voted at 113 shareholder meetings of 112 companies, on 797 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 4 times. Its most frequent area of disagreement was corporate governance (2 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals more often than John Hancock's funds as a whole (95.0% against 90.1%). It voted differently from most John Hancock funds on 115 items. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of John Hancock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.